THE FENWAY INSTITUTE

CONSENT TO TAKE PART IN A RESEARCH STUDY

Study Title:	SmartSteps: A context-aware, pre-exposure prophylaxis adherence intervention for individuals with substance use disorder
Principal Investigator:	Peter R. Chai, MD MMS
Study Contact:	Peter R. Chai, MD MMS, pchai@fenwayhealth.org or (617) 927-6266 or smartsteps@fenwayhealth.org

Call us at the number above with concerns, questions, or complaints about the research, study injuries, scheduling, or study visits. If you have questions about your rights as a participant in research, or wish to speak to someone not involved in the conduct of the study, please contact our **Human Research Protection Program** at: 617.927.6031, regulatory@fenwayhealth.org

Introduction

You may be eligible to take part in a research study. This form has important information that will help you decide whether to join. Ask the study staff to explain anything that is unclear to you or any questions you may have. You can also to talk to others, such as friends, family, or doctors, about your possible participation in this study.

If you decide to take part in the study, we will ask you to sign this form. We will give you a copy of the form to take home with you. It has information, including our contact information on the top of this page, which you should keep. We will also keep a signed copy of this form in our research records.

Key Information

We are asking you to take part in this research study because you identify as a man who has sex with men (MSM), are HIV negative, and are currently on or interested in starting oral pre-exposure prophylaxis (PrEP) for HIV prevention. We got your contact information because you use primary care at Fenway Health, you responded to an advertisement about the study, or your doctor or clinician referred you to the study.

Things you should know:

- The purpose of this study is to develop an algorithm that helps us recognize potential situations in which people might forget to take PrEP. Our ultimate goal is to use this algorithm to deliver messages to people via their phones to help teach PrEP adherence skills in situations when they might need them. In order to do this, we will be using a digital pill system to measure how you take your PrEP, and also ask you to install an app on your smartphone to capture anonymized data about your daily phone usage.
- Everyone who participates in this study will use the digital pill system with PrEP, and the smartphone app, for 60 days. At the end of the study, we will ask you to return to your primary care team to continue your regular PrEP prescription. If

you do not have a primary care team or are unable to continue PrEP, but you would like to keep taking PrEP, we will refer you to our HIV prevention team at Fenway Health or at Brigham and Women's Hospital.

- If you choose to participate, we will ask you to use the digital pill system to record your PrEP adherence. At your first study visit, when we teach you how to use the digital pill, we will also help you install Beiwe, a smartphone app that records general phone usage only during the study period.
- The study will take approximately two months (or 60 days) to complete. We will ask you to come to Fenway Health for a total of four study visits during this time.
- Risks or discomforts from this research fall into six categories: (1) if you are just starting PrEP, the risks associated with tenofovir/emtricitabine (TDF/FTC or Truvada™) as oral PrEP; (2) risk of swallowing the digital pill; (3) minimal risks associated with using the Beiwe app; (4) minor risks associated with having your blood drawn; (5) possibility of psychological discomfort when completing study questionnaires and interviews; and (6) risk of someone finding out that you are participating in a study on PrEP.
- You will directly benefit from this study by having access to free PrEP for the duration of this study.
- Whether you decide to take part in this study is your choice. You do not have to take part in the study and you are free to stop at any time.

You do not need to join this study to have access to PrEP. Instead of being in this study, you could receive PrEP from the same-day PrEP program offered by the Sexual Health Team at Fenway Health. Eligible participants who enroll in the program receive a 10-day supply of PrEP at their initial visit, and the remaining 90-day supply at their follow-up visit. Same-day PrEP is offered at Fenway Health's 1340 Boylston St. location or by calling (617) 267-0159.

Purpose of the Study

We are doing this study to understand how we can use patterns of how people use their smartphones daily (digital phenotyping), and how people take PrEP, in order to develop a text message based system that teaches skills around PrEP adherence. Doing this study will help advance how we teach PrEP adherence skills in individuals who may have difficulty taking PrEP on time, and will also help us understand whether there are ways in which we can predict when people might have difficulty taking PrEP so that we can help coach people through these situations.

In this study, we will ask you to use a digital pill system (DPS), which comprises a radiofrequency emitter coupled to a gelatin capsule that overencapsulates PrEP. When you take your PrEP in this digitized version, your stomach acid activates the radiofrequency emitter which then is acquired by a Reader device that you wear around your neck on a lanyard. The Reader collects and then sends your PrEP adherence data to a smartphone app, where you can view it at any time. In addition to this, we will also

ask you to install a digital phenotyping app called Beiwe onto your smartphone, which will collect anonymous data about your smartphone use.

The DPS is made by etectRx, a company based in Gainesville, FL, and is approved by the U.S. Food and Drug Administration (FDA) as a tool to detect medication ingestion. During the FDA approval process, etectRx completed multiple studies where participants ingested a digital pill and underwent an abdominal X-ray, which demonstrated that the digital pill dissolved and the sensor components passed in the stool. These studies also found that there was no damage to tissues or other electronic devices from the radiofrequency signal in the digital pill. During our previous studies using the digital pill, which we conducted in order to better understand PrEP adherence patterns, we have not encountered any side effects associated with the digital pill.

The study is being done at Fenway Health. It is being paid for by The National Institutes of Health. Seventy people will join this study. We plan to enroll all 70 participants at Fenway Health.

Study Drug Overview

In this study we will provide you with tenofovir/emtricitabine (TDF/FTC or Truvada™) as oral PrEP. You may be already on TDF/FTC as PrEP. If you are not on TDF/FTC, studies have shown that it is safe for you to switch from your current PrEP to TDF/FTC for the duration of the study and then return to your regular PrEP afterwards. TDF/FTC is FDA approved as PrEP approved to prevent HIV in people who are HIV negative. In clinical trials, the most common side effect of taking TDF/FTC are nausea, diarrhea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams and a rash. These side effects typically occur in the first few days of starting TDF/FTC and self-resolve. Rare side effects from TDF/FTC can include worsening kidney function, decreased bone mineral density (weakening of your bones), and lactic acidosis (an abnormal amount of lactic acid in your blood). As part of this study, we will check your medical record to see if you have had kidney function tests and liver function tests in the past six months. If you have not, we will draw baseline blood work to confirm you are medically safe to take TDF/FTC during the study.

What will happen in this research study?

Finding Out if you are Eligible (Screening)

After you sign this consent form, we will ask you some questions and do some tests to find out if you can be in the research study. If you have had some of these tests recently, we may not have to repeat them. We will:

- **Ask about your medical history,** including questions about your health, current medications, and any allergies.

- If necessary, we may **draw a blood sample,** so we can learn about your liver function, kidney function, and HIV status to make sure you can take PrEP.

If the results show that you can be in the study, we will continue. Once you've joined the study, it will take you approximately 2 months to complete this study. During that time, we will ask you to attend four study visits. This includes today's visit, a second visit in about 1-2 weeks, a third visit 30 days into the study, and a final visit approximately 60 days into the study (end of study). If there is a scheduling issue or if you can't stay to complete one of the study visits, we may schedule you for an additional study visit at your convenience to complete the study tasks. If this happens we will pay you for the additional study visit. We will also teach you how to use the digital PrEP pill, and ask you to download and activate the Beiwe mobile app. You will be asked to have your smartphone with you during the day and to you keep your smartphone charged during the 2-month study period.

Study Contact

During the course of the study, it may be important for us to contact you via text message, phone, email and/or notification from an app. We may contact you:

- To understand the reason for your missed dose if we notice that you have not taken a dose of PrEP over a 24-hour period.
- To ask about your sexual activity and substance use during a 24-hour period when we noticed that you did not take a dose of PrEP.
- If you have not connected the Reader device to your phone over the past week.
- If there is a new software update to the app or hardware update for the Reader.
- To ensure the digital pill technology is functioning properly.
- To remind you to keep the Beiwe app active on your smartphone.
- To remind you of an upcoming study visit.
- If you ask us to call you or contact you by email or text.

Please note, the Fenway Health standard is to communicate with research participants using encrypted platforms that meet the HIPAA security standards, such as MyChart or secure emails via the Mimecast Secure Messaging web app. This requires you to initially set up and activate an account with a password. You can then use the password to access secure emails sent to you from Fenway Health. Please note that secure messages from Fenway Health may be sent to your Spam inbox, unless you add the appropriate email addresses to your contact list. If you prefer, we can send you "unencrypted" email that is not secure and could result in the unauthorized use or disclosure of your information. If you want to receive communications by unencrypted email despite these risks, we will ask you to sign a section at the end of this consent form to indicate this. If you prefer, we can text you your visit reminders directly to your phone using our non-HIPAA compliant text platform, Dialpad, which is not secured in that way and could result in the unauthorized disclosure of your visit location, time, and date. If you want to receive communications by unencrypted text despite these risks, we

will ask you to sign a section at the end of this consent form to indicate this. Your preference to receive unencrypted emails and/or text messages will apply to emails and/or text messages sent from this research group/study only.

Digital Pill System

The digital pill system (DPS) to be used in this study was manufactured by etectRx and is approved by the FDA. It is made up of (1) a gelatin pill capsule that has a small radiofrequency emitter glued to the inside and PrEP, and (2) a wearable device, called a Reader. When you swallow the digital pill, your stomach acid breaks down the gelatin capsule and turns on the radiofrequency emitter. This emitter sends a radio signal off of your body to the wearable Reader. For this signal to be sent successfully, you need to be wearing the Reader when you take your medication. The Reader collects information about your ingestion event (date and time) and displays that information to you on a smartphone app. Once the radiofrequency emitter passes through your stomach, it turns off, goes through your intestine, and is excreted in your stool.

Digital Phenotyping (Beiwe)

Digital phenotyping is a technique where anonymized information about your smartphone is collected on an app and later analyzed for patterns of phone use. In this study, we are trying to see if any digital phenotypes might be related to PrEP nonadherence. You will be using an app called Beiwe, which we will help you download onto your phone for the duration of the study. You don't have to do anything with Beiwe once it is installed—it will run in the background. Depending on your phone's operating system, we will collect different types of information via Beiwe (summarized in the table below). It is important to note that none of this data is actually linked to your personal identifying information. For the study, you will be assigned a random ID number, so that, even in the event that this data was discovered by someone else, they would not know that the data is connected to you. To protect your confidentiality, all data from the smartphone application will be encrypted and uploaded to secure, password-protected servers. All study data will be seen only by the researchers or key study staff.

Android	**iOS**
Accelerometer	Accelerometer
Log file	Device motion
Bluetooth	GPS (on or off and general location)
GPS (on or off and general location)	Gyroscope (the way your phone moves around)
Gyroscope (the way your phone moves around)	iOS log file
Phone calls (time and duration of calls; no numbers or contact log details accessed)	Magnetometer (compass; i.e., the direction your phone is pointing)
Power status	Power status
Text message (number, frequency and time of messages, not numbers or identifiers)	Proximity (the way your phone is moving in space)
Wi-Fi usage	Reachability (ability to connect to wireless or data network)

Study Visits

The study will last for approximately 2 months. You will be expected to take part in four study visits during this time. The study visits will be conducted in-person and will last between 30 to 60 minutes each. If there is a scheduling issue or if you can't stay to complete one of the study visits, we may schedule you for an additional study visit at your convenience to complete the study tasks. If this happens we will pay you for the additional study visit.

Screening Visit (Visit 1) – 45 min: During this visit, we will explain the study to you in detail, review the Informed Consent Form with you, and answer your questions. If you choose to participate, we will ask you to sign the Informed Consent Form. After the informed consent process, you will be asked to complete the following activities:

- Complete a Locator Form that includes the contact information for a few close family/partners or friends, who you would be comfortable with us reaching out to about the study in the event that we cannot get in touch with you.
- You will be asked to sign a Medical Release Form, so the study team can review your recent laboratory work to confirm your eligibility to be on PrEP.
- If you do not have qualifying recent lab work, we will also conduct a blood draw (Chem 7, Hepatitis B status, liver function tests).
- If you are already on PrEP, we will collect blood work to look at the concentration of PrEP in your bloodstream. The total blood collection will be at most 2 tubes of blood (less than 10mL, or less than 2 teaspoons).
- We will use this blood draw to also conduct a rapid HIV test to ensure that you are HIV negative. If a blood draw does not need to be conducted, the rapid HIV test will be completed by finger prick. The results of this test are preliminary; if your test result is positive, it does not necessarily mean that you have HIV, and a negative result does not necessarily mean that you are not infected with HIV. In the event of a positive test result, we will refer you to care at Fenway Health, where you will receive additional "diagnostic" HIV testing to confirm your initial test result.
- You will be asked to complete the ASSIST assessment about your substance use, which will help us to determine whether you meet eligibility criteria.
- We will enroll you in ClinCard, which is a reloadable debit card system that will be used to pay you in this study. We will then pay you for attending this visit, and the money will be available for use immediately on your ClinCard.

Enrollment Visit (Visit 2) – 60 min: Once we have confirmed your eligibility after the Screening Visit (Visit 1), we will schedule you for the Enrollment Visit (Visit 2). During this visit, we will conduct the follow activities:

- You will be asked not to take your PrEP (if you are already taking PrEP) on the day of this visit, since you will be taking your first digital PrEP pill with us.
- You will be asked to complete a questionnaire about yourself, your sexual history, your use of PrEP, your attitudes about technology, and your trust in the medical system more generally.
- We will introduce you to the digital pill system and its equipment, and teach you

how to use the device. We will have you demonstrate you can use the digital pill system by having you swallow your first digital pill and recording the ingestion.

- We will then provide you with a 30-day supply of PrEP digital pills. Over the next few days, you will receive text messages from us to make sure you are not experiencing any problems with the technology.
- You will be asked to download the Beiwe app onto your phone and we will assist you with setting it up.
- We will pay you for attending this visit via your ClinCard.

Month 1 Visit (Visit 3) – 30 min: This visit will take place about one month (30 days) after Visit 2. Please remember to bring your digital pill equipment including leftover pills to this visit. During this visit, you will be asked to complete the following activities:

- We will review your digital pill adherence data over the past month. We will discuss any days that you did not take your PrEP to better understand the reasons behind any missed doses.
- We will help you troubleshoot any technological issues you have had with the digital pill or the Beiwe app.
- We will ask you to return any unused pills from the prior 30-day period. You will receive another 30-day supply of PrEP digital pills.
- We will pay you for attending this visit via your ClinCard.

Month 2 Visit (Visit 4) – 60 min: This visit will take place about 30 days after Visit 3. Please remember to bring all of your digital pill equipment with you including leftover pills to this visit. During this visit, you will be asked to complete the following activities:

- We will review your digital pill adherence data over the past month. We will discuss any days that you did not take your PrEP to better understand the reasons behind any missed doses.
- We will show you a map of your GPS activity (part of your digital phenotype) over the past 2 months. We will ask you about common locations to better understand how they may influence adherence.
- We will conduct a blood draw to collect one tube of blood (4mL, or less than one teaspoon) to measure the concentration of PrEP in your blood.
- We will conduct an audio recorded interview to understand your experiences using the digital pill and Beiwe during the study.
- You will return any unused pills from the prior 30-day period, and all of the equipment that you were using during the study period.
- We will pay you for attending this visit via your ClinCard.

At the end of the study, if you wish to continue taking PrEP, you should return to your primary care physician to continue your PrEP prescription. If you do not have a provider who prescribes PrEP, we will refer you to Fenway Health to continue PrEP.

Interim Surveys

Between study visits, if we detect that you did not take PrEP during a 24-hour period, we will send you a brief survey via the ID-Cap App. The survey will ask you to identify

the primary reason for missing your dose of PrEP. It will also ask you about whether you engaged in sexual activity and substance use during the prior 24 hours. This will help us better understand your HIV risk during a day when you did not take PrEP.

Research Study Plan

Activities	Screening Visit (Visit 1)	Enrollment Visit (Visit 2)	Month 1 Visit (Visit 3)	Month 2 Visit (Visit 4)
Informed consent	X			
Blood draw	X			X
Medical release form	X			
Locator form	X			
Quantitative assessment		X		
Digital pill system training		X	X	
Beiwe app training		X		
Review of adherence data			X	X
Exit interview				X

We may learn new things during the study that you should know about. If this happens, the researchers will tell you about new information that could affect your health and whether you want to continue to be in the study. You may be asked to sign a new informed consent form that shows that you have been told about the new information relating to this research study.

What if I stop the study early or am removed from the study before it is finished?

You can agree to be in the study now, change your mind later, and stop at any time. If you get care at Fenway Health, you can continue to get your regular medical care at Fenway Health. If you choose not to participate, it will not affect your care at Fenway Health now or in the future. There will be no penalty or loss of benefits.

The researchers may choose to stop your participation in this study at any time
You may be removed from the study if:

- Continuing in the study would be harmful to you.
- You need treatment that is not allowed in the study.
- You fail to follow instructions or miss study visits.
- The study is cancelled.

There may be other reasons that would require us to take you out of the study that we do not know at this time.

If you withdraw or are removed from the study, any data or samples collected from you before your withdrawal will still be used for this study.

What are the risks of this study? What will the study team do protect against these risks?

There are six categories of risks/discomforts associated with this study: (1) if you are just starting PrEP, the risks associated with tenofovir/emtricitabine (TDF/FTC or Truvada™) as oral PrEP ; (2) the risk of swallowing the digital pill; (3) the minimal risks associated with Beiwe; (4) the minor risks associated with having your blood drawn; (5) the possibility of psychological discomfort when completing study questionnaires and interviews; and (6) the psychological risk of someone finding out that you are participating in a study on PrEP. There may be risks related to this study that we don't know about or understand at this time. If we learn about new risks or anything else that could impact whether you choose to stay in the study, we will share that information with you.

Risks of Tenofovir/Emtricitabine (TDF/FTC or Truvada™)

Everyone in the research study will be watched carefully for side effects that may be related to taking TDF/FTC. We will monitor you during the study period while we are providing you with TDF/FTC If you experience any side effects, they may go away after you stop taking TDF/FTC. In clinical trials, the most common side effects of taking TDF/FTC are nausea, diarrhea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams and a rash. These side effects typically occur in the first few days of starting TDF/FTC and self-resolve. Rare side effects from TDF/FTC can include worsening kidney function, decreased bone mineral density (weakening of your bones), and lactic acidosis (an abnormal amount of lactic acid in your blood).

As with any drug, an allergic reaction can occur. Allergic reactions can be mild or more serious, and can even result in death. Common symptoms of an allergic reaction are rash, itching, skin problems, swelling of the face and throat, or trouble breathing. If you think you are having an allergic reaction, call the study doctor right away. If you are having trouble breathing, call 911 immediately.

Risk of the Digital Pill

- **Exposure to the radiofrequency transmitter:** The radiofrequency transmitter within the digital pill is made of silver and zinc. The transmitter itself is coated in an epoxy layer to prevent absorption of metals through your stomach or intestines. Even if you do become exposed to the radiofrequency transmitter, it contains significantly less than the FDA-recommended daily intake of these metals. We have had no adverse events related to the radiofrequency transmitter during any of our digital pill studies.
- **Retention of the digital pill in the stomach or intestines:** There is minimal risk that a digital pill would be retained in your stomach or intestines. We have had experience with over 2,000 ingestion events, where there have been no adverse events reported. A study involving 20 volunteers who swallowed the digital pill

and had abdominal X-rays 24 hours after the ingestion showed no evidence of retained digital pills in either the stomach or intestine.

- **Allergic reaction:** There is a risk of allergic reaction to the silver and zinc components of the radiofrequency transmitter, and to the gelatin pill capsule used to encase the radiofrequency transmitter and PrEP inside the capsule.
- There may be side effects or discomforts that are not yet known.

Risks of Beiwe

The risks associated with use of the Beiwe mobile application are minimal. You may experience slightly more (10-20%) battery usage on your phone, meaning you might need to charge your phone earlier in the day than what was your previous habit. Beiwe also uses your data plan or Wi-Fi connection to transmit digital phenotyping data to a secure online server. Sometimes this might cause other functions on your phone, like the web browser, to be a little slower, although past studies with Beiwe have shown that people do not notice a significant slowdown. Slightly more battery usage has not been a significant burden for participants in other studies using this smartphone app. You may experience some worry about a loss of privacy as a result of revealing your location and daily activities during the study, or as a result of receiving informational messages through the Beiwe app. However, the data collected by the Beiwe app do not tell us what you are doing, who you are with, and generally does not track your location when you are inside a building.

Risks of Blood Draw

You may have a bruise (a black and blue mark) or pain where we take the blood samples. There is also a small risk of infection, lightheadedness, and/or fainting.

Risks of Questionnaires and Interviews

The study questionnaires and interviews may include questions that you do not feel comfortable answering. It is possible that they may make you feel embarrassed or anxious. You may choose to skip questions that you do not want to answer.

Risk of Discoverability of PrEP Use and/or Study Participation

Although the risk is low, it is possible that your use of PrEP or participation in this study may be discovered if your smartphone is taken or accessed by someone else, and the digital pill app or Beiwe app is discovered, which might imply participation in this research. To minimize this risk, we will ensure that you have password protection (or Touch ID and/or Face ID, for iPhones) enabled on your smartphone during the enrollment process. Additionally, the icons for the digital pill app and Beiwe app are generic, and the apps do not refer to PrEP in any way. This will help to prevent unwanted disclosure of your use of PrEP. Finally, the digital pill gelatin capsule is

opaque, which will minimize the risk that someone looking at the digital pill could identify the particular medication inside of it.

What happens if I am hurt or become sick because I participated in this research study?

If you think you have been injured because of taking part in this research study, call (617) 927-6266 or email smartsteps@fenwayhealth.org.

If you are injured as a direct result of the study, Fenway Health will give you immediate necessary care for your injuries. Study staff will then direct you where to go if you need additional medical care. Fenway Health reserves the right to bill your insurance company or other third parties, if appropriate, for the care for the injury. We will try to have these costs paid for, but you may be responsible for some or all of them. For example, if the care is billed to your insurer, you will be responsible for any deductibles or co-payments required by your insurer.

Injuries sometimes happen even when no one is at fault. There are no plans to pay you or otherwise compensate you for an injury, should one occur. However, you are not giving up any of your legal rights by signing this form.

How might I be helped by participating in this study?

You will receive free PrEP during your time in this study (2 months). Additionally, what we learn from this study may help other people who are on PrEP to improve their adherence and understand situations where they might forget to take PrEP in the future.

What kind of information will be collected about me during this study?

The following types of data may be collected from you during this study:

- Medical record data: your most recent liver function, kidney tests, immunization data to ensure you are eligible to be on PrEP. You will be asked to fill out a Medical Release form before the study team can access this information.
- Questionnaire information, including self-reported information about yourself, your substance use, your sexual health and use of PrEP, your condom use, your attitudes about technology, and your trust of the medical system.
- Interview data, at the last study visit, around your experiences using the digital pill and Beiwe app during this study, and recommendations for future research. Audio files from these interviews will be sent to Landmark Associates, Inc. for transcription; potentially identifying information will be redacted during the transcription process. We will then delete all audio files from Landmark's portal.
- Blood tests (dried blood spots) that measure the amount of PrEP in your blood.

What will happen to my samples and information once this study is over?

We plan to keep your research data/specimens to use for future research at **Fenway Health.** Your name and other information that can be used to identify you will be kept safe and stored separately from the research data collected as part of the project. Access to the data/specimens will be restricted to the investigators from this study, other approved investigators, and other selected research staff. Your donated data/specimens will be stored using a code that will not contain identifying information. We will store data/specimens as long as they may be needed or until they are used up.

Once this study is complete, we may remove any information that could directly identify you from study data and samples, and use them for future research here at Fenway Health, share them with other researchers, or include them in a collection of samples and/or health information (Research Repository) from many different studies that researchers from all over could use. We will not ask for additional permission to do this.

You may request that we destroy your data/specimens that are still linked to your identity at any time. We will not be able to destroy or recall results from any test or analysis already conducted, or take back data or samples that have already been shared. If you want us to destroy your samples, please contact the Principal Investigator at pchai@fenwayhealth.org.

Will I get my research results?

We do not plan to return your individual research results to you or your doctor unless you specifically ask us to do so. If you would like, we will send metrics around how well you are taking your PrEP to your primary care physician (PCP) after each monthly study visit. Your results are a stepping stone in learning about health and disease. Most of what we learn in this study will not be relevant to your personal health. There is a small chance that researchers could find something that might be important to your health. If this happens, we may try to contact you to find out if you would like to learn more.

Results from this study will be submitting for publication in medical journals and academic presentations. However, no information that can identify you will be disclosed. In other words, your name will not be used in any reports and no personal information that can identify you will be included. Confidentiality will be maintained to the extent allowed by law. We will also report study results to the National Institutes of Health (NIH) during annual reporting and at invited events.

How will you protect my privacy?

Your privacy is a top priority. If you agree to take part in this research study, your personal information will not be given to anyone unless we receive your permission or the law requires it.

- All the information we collect for this research study will be stored in locked file cabinets and kept in secure, password-protected computer files. All study visits and procedures will take place in private.
- We will also create a unique study code for the research information we collect about you and label your study files with that code instead of your name. Only the study team will have the key to this code.
- The results of this research may be published in a medical book or journal or be used for teaching purposes. However, your name or identifying information will not be used.

This research is covered by a Certificate of Confidentiality (Certificate) from the NIH. This means we may not disclose or use study information that may identify you if there is a court subpoena, unless you agree. We may still report your medical information if you need medical help, or if there is a risk of harm to yourself or others, as the law requires. A Certificate does not mean the government approves of our project. You should understand that a Certificate does not prevent you from voluntarily releasing information about yourself or your involvement in this research. We will not use the Certificate to prevent disclosure for any purpose you have consented to in this informed consent document or any later authorization.

A description of this study will be posted on a public website, ClinicalTrials.gov, and summary results of this study will be posted on this website at the conclusion of the research. No information that can identify you will be posted.

Privacy and Information Sharing Authorization

You may have the right to find out if information collected for this study was shared with others for research, treatment, or payment. You may not be allowed to review the information, including information recorded in your medical record, until after the study ends. When the study is over, you will have the right to access the information again.

You can withdraw from the study and end your permission for Fenway Health to use or share the information that was collected as part of the research; however, you cannot get back information that was already shared with others. Once you remove your permission, no more identifiable information about your health (“health information”) will be collected. If you wish to withdraw your health information, please contact the research team.

In this study, we may collect health information about you from:

- Past, present, and future medical records
- Research visits, tests, interviews, and questions.

Your health information is protected by a law called the Health Information Portability and Accountability act (HIPAA). In general, anyone who is involved in this research,

including those funding and regulating the study, may see the data, including information about you. The following people may see, use, and share your research health information:

- Research staff at Fenway Health involved in this study;
- Medical staff at Fenway Health directly involved in your care;
- Other research investigators and centers that are a part of this study, including people who oversee the research;
- People at Fenway Health who oversee, advise, and evaluate research and care, including the Fenway Health Institutional Review Board;
- Non-research staff within Fenway Health who need this information to do their jobs (such as for treatment, payments, or health care operations);
- People from agencies and organizations that provide accreditation and oversight of research;
- People that oversee the study information such as data safety monitoring boards, clinical research organizations, data coordinating centers, and others;
- Sponsors or others who fund the research, including the government or private sponsors;
- Companies that manufacture drugs or devices use in this research;
- Federal and state agencies that oversee or review research information, such as the FDA, the Department of Health and Human Services, the National Institutes of Health, and public health and safety authorities;
- People or groups that are hired to provide services related to this research or research at Fenway Health, such as laboratories;
- Your health insurer for portions of the research and related care that are considered billable;
- Public health and safety officials (for instance, if we learn information that could mean that harm could come to you or others we may need to report this, as required by law);
- The Massachusetts Department of Public Health (MDPH), if we learn that you have a reportable sexually transmitted infection, as Massachusetts law requires;
- Staff at ARx Pharmacy, who will be assembling the digital PrEP pills;
- Landmark Associates, Inc., who will be transcribing the audio-recorded interviews and redacting potentially identifying information.

The main reasons why we may share this information include:

- To conduct the study;
- To make sure the study meets all legal and organizational requirements;
- To monitor the safety of participants in the study.

We will use and disclose your protected information only as described in this form; however, people outside Fenway Health who receive your information may not be

covered by this promise. We will try to ensure that everyone who needs to see your information keeps it confidential, but we cannot guarantee this.

Because research is ongoing, we cannot give you an exact time of when we will destroy this information. Researchers may continue to use your data for many years.

Will I be paid for taking part in this study?

You will receive up to $150 for your participation in this study. We are using a reloadable debit card system called ClinCard, which is used for Fenway Health studies.

At your Screening Visit (Visit 1), you will receive your personal ClinCard, which you will hold onto for the duration of your participation in this study. At the completion of each study visit, we will remotely load the card with the specific compensation amount associated with that visit (see table below). You can use your ClinCard like a debit card – there are no transaction fees or monthly maintenance fees that you will need to cover. We will ask for your phone number when setting up your ClinCard, which helps us register the card to you. If you lose your ClinCard, we are able to provide one replacement card per study participant here at Fenway, at no cost to you.

Study Visit	Compensation
Screening Visit (Visit 1)	$30
Enrollment Visit (Visit 2)	$30
Month 1 Visit (Visit 3)	$40
Month 2 Visit (Visit 4)	$50
Total	**$150**

You are also eligible to receive up to $5.00 per visit ($20 total) in reimbursement for travel expenses to and from all your visits as an additional payment on your ClinCard (this is separate from the study visit compensation). If travel presents a barrier to participation, you may inform study staff to discuss alternative transportation options.

What will I have to pay for if I take part in this research study?

There is no cost to you related to taking part in this research study.

STUDY OPTIONS

This page includes tests, procedures, and study choices that are not required in order to take part in this study. You can say yes or no and still participate.

As outlined on page 4 of this consent form, receiving email communications is a necessity for participation in this study. The options of encrypted and unencrypted email, and the potential risks of both, have been outlined above. Would you like us to send your emails encrypted using Mimecast?

_____ **YES**, only send me **ENCRYPTED** emails. I understand I will need to click a link within the email to read the message.

_____ **NO**, I prefer to receive **UNENCRYPTED** emails. I understand this is less secure.

As outlined on page 4 of this consent form, you have the option to receive visit reminders from the study team via text using our non-HIPAA compliant text platform, Dialpad, which is not secured and could result in the unauthorized disclosure of your visit location, time, and date. The option to receive unencrypted text messages via Dialpad and the potential risks have been outlined above. Would you like to receive visit reminders via unencrypted text despite these risks?

_____ **YES**, I consent to receive unencrypted text messages via Dialpad. I understand this is less secure.

_____ **NO**, I do not consent to receive unencrypted text messages via Dialpad.

As outlined on page 12 of this consent form, you have the option for the study team to send your monthly adherence information to your primary care provider (PCP). Would you like us to send your monthly adherence information to your PCP?

_____ **YES**, send my monthly adherence information to my PCP.

_____ **NO**, do not send my monthly adherence information to my PCP.

Extra Samples and Information for Research Repository

We would like to use your study information, adherence data and digital phenotyping data to include in a research repository for use in the future. The purpose of this repository is to understand future contexts around PrEP adherence and digital phenotypes that might related to events around PrEP ingestion. This would include development of machine learning protocols around digital phenotypes. We may also keep your information if you are willing to be contacted to participate in future digital pill related research at Fenway. Samples will be stored until they are used up. Information will be kept indefinitely. We will store your samples and information with a code that thinks them to your identity. If you agree to allow your coded samples and information to be kept for future research, you are free to change your mind at any time. We ask that

you contact us in writing and let us know you are withdrawing your permission. While we cannot take back any samples and information we have already used or shared, we will destroy any of your samples or information that we still have.

INITIAL one of the following:

_____ I **AGREE** to allow my coded samples and information to be included in the research repository.

_____ I **DO NOT AGREE** to allow my coded samples and information to be included in the research repository.

Informed Consent and Authorization

Person Obtaining Consent

- I have explained the research to the study participant.
- I have answered all questions about this research study to the best of my ability.

Person Obtaining Consent (Signature) **Date/Time**

Statement of Person Giving Informed Consent and Authorization

- I have read this consent form.
- I have been informed about the purpose of the research study, the procedures that I will undergo, and the possible risks, discomforts, and benefits I may experience.
- I have had the opportunity to ask questions and my questions have been answered.
- I understand that this is a choice, and know the alternatives to my participation.

I give my consent to take part in this research study. I give permission to Fenway Health and its collaborators to use and disclose my protected health information as described above.

Subject's Name (Printed)

Subject (Signature) **Date/Time**

TFI USE ONLY:

QC Initials	**QC Date**